Our Team

Moshe joined Moebius in 2015 following over 20 years of experience in the pharma and healthcare industries. At Novartis Pharmaceuticals, Moshe held positions in marketing, business developing and licensing, and immediately prior to joining Moebius, was the Franchise Head responsible for sales and marketing of the hematology franchise in Central America and the Caribbean region. Moshe also serves as Executive Chairman of Everads Therapy Ltd, a startup developing a novel drug delivery platform for ophthalmic indications. Moshe earned his MBA from INSEAD, and holds a BSc in Business & Management from Yeshiva University, New York.

Ronny is an expert in process development, scale-up, analytics and CMC (Chemistry, Manufacturing & Controls), with significant expertise in GMP (Good Manufacturing Practice) issues in the manufacturing of various pharmaceutical products, including small molecules, recombinant proteins, glycans, pegylation, liposomes and viruses/phages for both ethical and biosimilar/generic Drugs. Prior to joining Moebius, Ronny held management positions over the course of 23 years at InterPharm, Merck Serono, Teva Pharmaceuticals Industries, InSight Biopharmaceuticals and BiomX. Ronny holds a PhD from the Weizmann Institute and an MBA from the Polytechnic Institute of New York.

Roni joined Moebius in 2020 with 22 years of R&D experience in the biotech industry. In the last 12 years before joining Moebius, he served in executive positions in biomaterials companies in the cartilage repair/osteoarthritis arena.  While at Regentis Biomaterials, Roni focused on deciphering the lead product mechanism of action as well as development of an injectable product for osteoarthritis. At Moebius, Roni strengthens the science behind the company and develops next generation products for the company pipeline. Prior to joining Moebius, Roni held management positions at Regentis Biomaterials (VP R&D), Procore (CTO), Prochon (CTO), and QBI (Protein Unit, Head). Roni holds a B.Sc. from McGill University, an M.Sc. and a Ph.D. from the Weizmann Institute and an MBA from the College of Management Academic Studies (COLMAN).

Dana joined Moebius after 12 years consulting, managing regulatory affairs and heading up business development for global MedTech and Digital Health companies. For Arcondis, she founded the company’s APAC subsidiary and served as its general manager, and as an independent consultant she built go-to-market, fundraising, regulatory and marketing strategies for startups in Southeast Asia. She also served as Regulatory Affairs Director for Perflow Medical, a successful RAD Biomed venture. Dana holds a B.Sc. and M.Sc. from the Technion, Israel Institute of Technology, and an Executive MBA from the leading business school INSEAD

Rany is an experienced researcher skilled in biotechnology, nanoparticles, data analysis, drug delivery, and protein conjugation. He received his Ph.D. in nanotechnology for drug delivery from Università degli Studi di Milano-Bicocca, and his M.Sc. and B.S. in chemistry and biology from the Hebrew University of Jerusalem. In addition, he is experienced in machine learning and AI/Deep Learning and statistical data analysis.

Yonatan is a skilled CPA with extensive experience in the pharmaceutical and medical device industries. Prior to joining Moebius Medical, he played a key role in the transformation of the BiomX Group into a publicly-traded company (Nasdaq: PHGE), serving as its Corporate Controller. He also served as CFO of IOPtima Ltd., a medical device company, and currently holds the positions of CFO of Everads Therapy Ltd. and Director of Finance at Chemomab Therapeutics (Nasdaq: CMMB). Yonatan holds a B.Sc. in Accounting and Business Management from The College of Management Academic Studies.

Prof. Barenholz is the Head of the Liposome and Membrane Research Lab at the Hadassah Medical School of the Hebrew University of Jerusalem. He has co-authored more than 440 publications, is a co-inventor of more than 56 allowed patents, and is one of the key inventors and developers of Doxil®, an anti-cancer drug that has been used to treat over 1 million cancer patients. Currently, Prof. Barenholz and his teams are developing 6 additional liposomal drugs for different indications based on a crosstalk between biology, nanotechnology, and medicine. Prof. Barenholz’s achievements have been recognized by his receipt of national and international prizes, including the Israel Prime Minister EMET Prize in the Exact Sciences (nanotechnology – nanomedicine) in 2020.

Prof. Schnitzer is Professor of Physical Medicine and Rehabilitation, Anesthesiology and Rheumatology at the Northwestern University’s Feinberg School of Medicine. His group’s research is focused on understanding and treatment of chronic pain, including osteoarthritis and the effect of weight-loss therapies on pain and cardiovascular outcomes, and he has been the Principal Investigator in a wide range of studies on new therapeutic approaches. Prof. Schnitzer received his MD from Harvard Medical School and his PhD from London’s Imperial Cancer Research Institute.

Prof. Conhan is Director of the NIHR Leeds Biomedical Research Centre, Professor of Musculoskeletal Medicine for the University of Leeds, Honorary Consultant Rheumatologist for LTHT, and a NIHR Senior Investigator Emeritus. He is a EULAR methodologist and Deputy Chair of the international outcomes group OMERACT. He previously chaired the EULAR Standing Committee on MSK imaging and NICE osteoarthritis clinical guidance committees. He has authored more than 700 publications, is co-editor of the Oxford Textbook of Rheumatology, and has won several international rheumatology research awards.

Prof. Chevalier is a professor of Rheumatology at Paris University XII and Head of the Rheumatology Department at Henri Mondor Hospital, both in Créteil, France. His research currently focuses on cartilage metabolism and new treatment options for osteoarthritis. He headed the Osteoarthritis Section at the French Society of Rheumatology and is a member of the Osteoarthritis Research Society International (OARSI) and American College of Rheumatology (ACR).

Moshe joined Moebius in 2015 following over 20 years of experience in the pharma and healthcare industries. At Novartis Pharmaceuticals, Moshe held positions in marketing, business developing and licensing, and immediately prior to joining Moebius, was the Franchise Head responsible for sales and marketing of the hematology franchise in Central America and the Caribbean region. Moshe also serves as Executive Chairman of Everads Therapy Ltd, a startup developing a novel drug delivery platform for ophthalmic indications. Moshe earned his MBA from INSEAD, and holds a BSc in Business & Management from Yeshiva University, New York.

Prof. Barenholz is the Head of the Liposome and Membrane Research Lab at the Hadassah Medical School of the Hebrew University of Jerusalem. He has co-authored more than 440 publications, is a co-inventor of more than 56 allowed patents, and is one of the key inventors and developers of Doxil®, an anti-cancer drug that has been used to treat over 1 million cancer patients. Currently, Prof. Barenholz and his teams are developing 6 additional liposomal drugs for different indications based on a crosstalk between biology, nanotechnology, and medicine. Prof. Barenholz’s achievements have been recognized by his receipt of national and international prizes, including the Israel Prime Minister EMET Prize in the Exact Sciences (nanotechnology – nanomedicine) in 2020.

Prof. Nava Zisapel (Emeritus, Tel Aviv University), founder and CEO of Neurim Pharmaceuticals, is a renown neuroscientist with research focus on melatonin, sleep, and neurosecretion.
Professor Zisapel is the principal author of over 200 papers in peer-reviewed journals and principal inventor of over 60 patents. She led the development and commercialization of the company’s first drugs and is deeply involved in discovering and developing newel medicines that hold promise for patients with CNS-related conditions.

Bob Trachtenberg joined Yissum in 2006 as its first General Counsel. In this role, he manages all aspects of Yissum’s legal activities, including technology licensing and intellectual property protection. An attorney with over 43 years of experience in the US and Israel, Bob previously served as General Counsel of Keryx Biopharmaceuticals (NASDAQ: KERX) and of Accent Software International. He earned his JD from New York University and his BA from Binghamton University.

David is a senior-level executive with strong background in global high-tech, biomed, biotech and pharma startup ecosystems. Since January 2019, Mr. Zigdon has served as CEO of MIGAL Galilee Research Institute, an independent Israeli applied research organization. Before that, Mr. Zigdon served for nine years as President and CEO of RAD Biomed, an Israel-based biomed accelerator, and for two decades as CEO/CFO for high tech firms, including Bynet, Bynet Electronics, Radcom (Nasdaq: RDCM), Magic Software (Nasdaq: MGIC) and Time To Know. Mr. Zigdon is a certified public accountant and holds a BA Economics and an LLM degree from Bar Ilan University.